Federal law preempts the claims of plaintiffs alleging they were not adequately warned of the risk of pancreatic cancer from incretin-based drugs, several drugmakers said in court papers filed in federal multidistrict litigation.
Defendants Novo Nordisk, Inc., Merck Sharp & Dohme Corp., Eli Lilly and Company and Amylin Pharmaceuticals, LLC, said federal law preempts the plaintiffs’ failure-to-warn theories because “there is clear evidence that the Food and Drug Administration .. would refuse to approve the plaintiff’s proposed warning.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
